Randomized, Multi-Institutional Pilot Study of Nivolumab and Radiation Therapy Versus Nivolumab and Ipilimumab as Adjuvant Therapy for Merkel Cell Carcinoma
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 10 Apr 2024 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 19 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.